XRAY is a reliable source of cancer-related news and information.
XRAY Quarterly Digest
FORCE developed our XRAY-Behind the Headlines program to help people separate relevant cancer news from hype by providing honest evaluations of cancer research reported in the media. 
 
The XRAY Quarterly Digest provides a compilation of XRAY reviews published over the last three months.
Lynparza
Breaking Breast Cancer Color Barriers and Building Bridges

Our partners and colleagues at For the Breast of Us have written a guide on how to be an accomplice for women of color affected by breast cancer. Please read and share this blog with your community.


Read the Blog








 
200th XRAY Post
Promising research for metastatic breast cancer for women with inherited PALB2 mutations

Lynparza may improve outcomes for women with metastatic breast cancer, including those with an inherited PALB2 mutation. Women with an acquired tumor mutation in BRCA1 or BRCA2 also benefited. Read our XRAY-Behind the metastatic breast cancer headlines. 

Read the Review
Tukysa combination treatment
Tukysa, newly approved for metastatic breast cancer, also helps those with brain metastases

The FDA approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. Read more about the treatment behind the cancer headlines.


Read the Review
 
Lynparza
Lynparza in combination with Avastin is approved for maintenance therapy for advanced ovarian cancer
 

The FDA approved the first drug combination for first-line maintenance therapy for some women with advanced ovarian cancer. The approval was based on the ongoing PAOLA-1 clinical trial.  Read our XRAY-Behind the ovarian cancer headlines.


Read the Review
 
Trodelvy
Trodelvy gains approval for treatment of metastatic triple-negative breast cancer  
 
The drug Trodelvy is a new option for people metastatic triple-negative breast cancer who have had two or more therapies for metastatic disease. Read behind the headlines for more about this new treatment.

Read the Review
 
Contralateral breast cancer
What is the risk of contralateral breast cancer in women with inherited mutations?  
 
Women with an inherited mutation in TP53 have an increased risk for contralateral breast cancer (breast cancer in the opposite breast) - even greater than the risk of women with a BRCA1 or BRCA2 mutation.  Read our XRAY-Behind the breast cancer headlines review. 

Read the Review
 
Metastatic prostate cancer
Two newly approved PARP inhibitors for metastatic prostate cancer

The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. Read more behind the cancer headlines.


Read the Review
 
Zejula
Women with advanced ovarian cancer can use Zejula for maintenance therapy

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy option for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy.



Read the Review
 
                   .  
 
 
Facing Our Risk of Cancer Empowered, 16057 Tampa Palms Blvd. W #373, Tampa, FL 33647
 https://go.pardot.com/webmail/293442/781549610/fdbaed419814cf423724fce3627da4c2fbc7f637e3023744c6672bd54855c820 update preferences https://go.pardot.com/unsubscribe/u/293442/fdbaed419814cf423724fce3627da4c2fbc7f637e3023744c6672bd54855c820/781549610

FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCES AGAINST HEREDITARY CANCER®, PREVIVOR® and the FORCE Ribbon Design are registered trademarks of FORCE-Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE’s trademarks is prohibited.